{
    "clinical_study": {
        "@rank": "144514", 
        "acronym": "SUL", 
        "arm_group": {
            "arm_group_label": "sulpiride 50 mg", 
            "arm_group_type": "Other"
        }, 
        "brief_summary": {
            "textblock": "The present study was adopted to evaluate the pharmacokinetics of sulpiride after oral\n      administration."
        }, 
        "brief_title": "Therapeutic Drug Monitoring and Pharmacokinetic Compartmental Analysis of Sulpiride After Oral Administration to Healthy Volunteers", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "The present study was adopted to evaluate the pharmacokinetics of sulpiride after\n      administration of single oral doses of 50 mg in an open-label, one-way study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  At least 18 years old and not more than 45 healthy male volunteers\n\n          -  Actual weight no more than \u00b1 30% from ideal body weight based on sex, height, and\n             body frame\n\n          -  Who had passed all the screening parameters\n\n          -  Free of any drug exposure known to interfere with the pharmacokinetics or assay of\n             sulpiride for at least 10 days prior to the study\n\n          -  Who had to be able to communicate effectively with study personnel, be literate, and\n             able to give consent.\n\n        Exclusion Criteria:\n\n          -  A clinically significant abnormal physical exam, medical history, or laboratory\n             studies If they showed a sitting SBP of >140 or <100 mmHg, DBP > 90 or <60mm Hg, or a\n             pulse rate of > 95 or < 50 beats/min at screening A history of serious intolerance,\n             allergy, or sensitivity to fexofenadine The use of any prescription drug within the\n             previous month or use of any over-the-counter medication (with the exception of\n             acetaminophen) within the past 14 days A history of blood dyscrasias A history of\n             alcohol or drug abuse within the past year Donation of blood during the 8 weeks prior\n             to the study or plans to donate blood during or within 8 weeks of completing the\n             study Unable to tolerate vein puncture and multiple blood samplings Any\n             surgical/medical condition that might alter drug absorption, distribution,\n             metabolism, or excretion Cannot follow instructions, in the opinion of the\n             investigator."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01777685", 
            "org_study_id": "PPT3"
        }, 
        "intervention": {
            "arm_group_label": "sulpiride 50 mg", 
            "intervention_name": "Sulpiride", 
            "intervention_type": "Drug", 
            "other_name": "Dogmatil"
        }, 
        "intervention_browse": {
            "mesh_term": "Sulpiride"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Sulpiride", 
            "Therapeutic drug monitoring", 
            "Pharmacokinetics"
        ], 
        "lastchanged_date": "January 28, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Damanhour", 
                    "country": "Egypt"
                }, 
                "name": "Pharmaceutics Department, Faculty of Pharmacy, Damanhour University"
            }
        }, 
        "location_countries": {
            "country": "Egypt"
        }, 
        "number_of_arms": "1", 
        "official_title": "Therapeutic Drug Monitoring and Pharmacokinetic Compartmental Analysis of Sulpiride", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Egypt: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Assessment of the pharmacokinetics using compartmental and non compartmental analysis of sulpiride after oral administration", 
            "measure": "\u2022Assessment of the bioequivalence of the oral suspension formulation, the oral solution formulation, and the marketed tablet formulation of levofloxacin, on Days 1, 2, and 3, using the marketed tablet as the reference.  Pharmacokinetics of sulpiride", 
            "safety_issue": "Yes", 
            "time_frame": "The pharmacokinetic analysis is done after blood sampling"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01777685"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Damanhour University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Damanhour University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}